相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Real-World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B-Cell Lymphoma in the U.S
Xiaoqin Yang et al.
ONCOLOGIST (2021)
Costs associated with follicular lymphoma among individuals diagnosed with non-Hodgkin lymphoma: a longitudinal analysis using SEER-Medicare data
Husam Albarmawi et al.
LEUKEMIA & LYMPHOMA (2020)
Financial burden of thyroid cancer in the United States: An estimate of economic and psychological hardship among thyroid cancer survivors
Courtney E. Barrows et al.
SURGERY (2020)
Comparison of the Financial Burden of Survivors of Head and Neck Cancer With Other Cancer Survivors
Sean T. Massa et al.
JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY (2019)
Long-term fatigue in survivors of non-Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross-sectional study
Nicolas Mounier et al.
CANCER (2019)
Cost burden of diffuse large B-cell lymphoma
R. Andrew Harkins et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2019)
Burden of illness of follicular lymphoma and marginal zone lymphoma
Neerav Monga et al.
ANNALS OF HEMATOLOGY (2019)
Retrospective analysis of first-line treatment for follicular lymphoma based on outcomes and medical economics
Manaka Muneishi et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2018)
Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma
Richard T. Maziarz et al.
LEUKEMIA & LYMPHOMA (2018)
The landscape of new drugs in lymphoma
Anas Younes et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study
Annalisa Chiappella et al.
LANCET ONCOLOGY (2017)
Economic Burden for Lung Cancer Survivors in Urban China
Xin Zhang et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2017)
Estimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World Data
Mark D. Danese et al.
MEDICAL CARE (2016)
Clinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data
Chakkarin Burudpakdee et al.
JOURNAL OF MEDICAL ECONOMICS (2016)
Impact onMedical Cost, Cumulative Survival, and Cost-Effectiveness of Adding Rituximab to First-Line Chemotherapy for Follicular Lymphoma in Elderly Patients: An Observational Cohort Study Based on SEER-Medicare
Robert I. Griffiths et al.
JOURNAL OF CANCER EPIDEMIOLOGY (2012)
Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA
Olivier Fitoussi et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Economic impact of disease progression in follicular non-Hodgkin lymphoma
Roy Beveridge et al.
LEUKEMIA & LYMPHOMA (2011)
Economic Burden of Follicular Non-Hodgkin's Lymphoma
Talia Foster et al.
PHARMACOECONOMICS (2009)
Medical costs associated with non-Hodgkin's lymphoma in the United States during the first two years of treatment
Lucie Kutikova et al.
LEUKEMIA & LYMPHOMA (2006)
Estimating log models: to transform or not to transform?
WG Manning et al.
JOURNAL OF HEALTH ECONOMICS (2001)
分享论文
